Novartis sees India Glivec ruling indicative of IP 'de-recognition'
This article was originally published in Scrip
Executive Summary
India's Supreme Court has dismissed with costs Novartis' plea in the crucial case concerning its anticancer Glivec (imatinib mesylate) and the interpretation of the controversial Section 3(d) provision of India's patent law (scripintelligence.com, 1 April 2013).